South Dakota Investment Council Purchases 9,529 Shares of IQVIA Holdings Inc. $IQV

South Dakota Investment Council lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 10.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 97,241 shares of the medical research company’s stock after acquiring an additional 9,529 shares during the quarter. South Dakota Investment Council owned approximately 0.06% of IQVIA worth $18,470,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Physician Wealth Advisors Inc. grew its position in shares of IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after buying an additional 134 shares during the period. Westside Investment Management Inc. raised its stake in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the period. Atlantic Union Bankshares Corp bought a new position in shares of IQVIA during the 3rd quarter valued at about $36,000. Root Financial Partners LLC bought a new position in IQVIA in the third quarter valued at approximately $43,000. Finally, Hantz Financial Services Inc. raised its holdings in shares of IQVIA by 92.0% during the third quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock worth $46,000 after acquiring an additional 115 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 2.4%

IQV stock opened at $174.48 on Tuesday. The company has a market cap of $29.61 billion, a price-to-earnings ratio of 22.20, a P/E/G ratio of 1.72 and a beta of 1.40. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The business has a 50 day moving average price of $211.19 and a two-hundred day moving average price of $208.02. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter in the prior year, the firm posted $3.12 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. TD Cowen upped their target price on shares of IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. Evercore reaffirmed an “outperform” rating and set a $225.00 price objective on shares of IQVIA in a research report on Thursday, February 5th. Truist Financial decreased their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. Mizuho set a $215.00 target price on IQVIA in a research note on Monday, February 23rd. Finally, BMO Capital Markets set a $250.00 price target on shares of IQVIA in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $231.80.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.